Published in Bone on March 24, 2012
Bone turnover markers: use in osteoporosis. Nat Rev Rheumatol (2012) 1.25
Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics. Osteoporos Int (2015) 1.02
Short-term and long-term effects of osteoporosis therapies. Nat Rev Endocrinol (2015) 0.98
The management of osteoporosis in breast cancer survivors. Maturitas (2012) 0.84
Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis. Osteoporos Int (2016) 0.83
Bisphosphonates in the management of thalassemia-associated osteoporosis: a systematic review of randomised controlled trials. J Bone Miner Metab (2014) 0.81
Cancel the denosumab holiday. Osteoporos Int (2016) 0.76
Serum Markers of Bone Turnover and Angiogenesis in Patients With Bisphosphonate-Related Osteonecrosis of the Jaw After Discontinuation of Long-Term Intravenous Bisphosphonate Therapy. J Oral Maxillofac Surg (2015) 0.75
Raloxifene Improves Bone Mechanical Properties in Mice Previously Treated with Zoledronate. Calcif Tissue Int (2017) 0.75
Effects of Zoledronate on Mortality and Morbidity after Surgical Treatment of Hip Fractures. Adv Orthop (2016) 0.75
Intravenous zoledronate for osteoporosis: less might be more. Ther Adv Musculoskelet Dis (2016) 0.75
The 5-year impact of a single dose of zoledronate. Bonekey Rep (2012) 0.75
Dosing Strategies of Bone-Targeting Agents-Reply. JAMA Intern Med (2015) 0.75
Bisphosphonate therapy: how long is long enough? Osteoporos Int (2015) 0.75
Effect of single-dose dexamethasone on acute phase response following zoledronic acid: a randomized controlled trial. Osteoporos Int (2017) 0.75
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med (2007) 18.27
Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med (2009) 13.57
Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ (2010) 10.85
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. BMJ (2008) 5.14
Paget's disease of bone: an endocrine society clinical practice guideline. J Clin Endocrinol Metab (2014) 4.63
The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res (2012) 4.15
The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab (2007) 4.01
Effects of calcium supplementation on serum lipid concentrations in normal older women: a randomized controlled trial. Am J Med (2002) 2.86
Randomized controlled trial of calcium in healthy older women. Am J Med (2006) 2.78
Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc (2008) 2.75
Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res (2015) 2.74
Calcium and vitamin D supplements and health outcomes: a reanalysis of the Women's Health Initiative (WHI) limited-access data set. Am J Clin Nutr (2011) 2.44
Genome-wide association study using extreme truncate selection identifies novel genes affecting bone mineral density and fracture risk. PLoS Genet (2011) 2.34
Randomised trials in general practice--a New Zealand experience in recruitment. N Z Med J (2003) 2.23
Randomized controlled trial of calcium supplementation in healthy, nonosteoporotic, older men. Arch Intern Med (2008) 2.10
Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J Bone Miner Res (2011) 2.07
Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res (2008) 2.04
Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res (2012) 1.98
Maori have worse outcomes after coronary artery bypass grafting than Europeans in New Zealand. N Z Med J (2013) 1.96
Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J Bone Miner Res (2012) 1.92
Effects of calcium supplementation on body weight and blood pressure in normal older women: a randomized controlled trial. J Clin Endocrinol Metab (2005) 1.91
The effects of seasonal variation of 25-hydroxyvitamin D and fat mass on a diagnosis of vitamin D sufficiency. Am J Clin Nutr (2007) 1.83
Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone (2007) 1.73
Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab (2010) 1.68
Decreased bone density in men on methadone maintenance therapy. Addiction (2010) 1.63
The management of acute coronary syndrome patients across New Zealand in 2012: results of a third comprehensive nationwide audit and observations of current interventional care. N Z Med J (2013) 1.60
Agreement between stereoscopic photographs, clinical assessment, Heidelberg retina tomograph and digital stereoscopic optic disc camera in estimating vertical cup:disc ratio. Clin Experiment Ophthalmol (2005) 1.58
Goal-directed treatment of osteoporosis. J Bone Miner Res (2013) 1.58
Further development of an illness perception intervention for myocardial infarction patients: a randomized controlled trial. J Psychosom Res (2009) 1.58
Calcium supplementation: balancing the cardiovascular risks. Maturitas (2011) 1.56
Skeletal phenotype of the leptin receptor-deficient db/db mouse. J Bone Miner Res (2011) 1.55
WNT16 influences bone mineral density, cortical bone thickness, bone strength, and osteoporotic fracture risk. PLoS Genet (2012) 1.55
Assessment of tophus size: a comparison between physical measurement methods and dual-energy computed tomography scanning. J Clin Rheumatol (2012) 1.55
The skeletal effects of the tyrosine kinase inhibitor nilotinib. Bone (2011) 1.50
Effect of providing information about normal test results on patients' reassurance: randomised controlled trial. BMJ (2007) 1.49
Association of fat-free mass and training status with left ventricular size and mass in endurance-trained athletes. J Am Coll Cardiol (2004) 1.48
Defining vitamin D deficiency. N Z Med J (2007) 1.45
Acute primary angle closure attack does not cause an increased cup-to-disc ratio. Ophthalmology (2010) 1.45
Abdominal aortic calcification on vertebral morphometry images predicts incident myocardial infarction. J Bone Miner Res (2010) 1.45
Does calcium supplementation increase cardiovascular risk? Clin Endocrinol (Oxf) (2010) 1.44
Should measurement of vitamin D and treatment of vitamin D insufficiency be routine in New Zealand? N Z Med J (2012) 1.42
CLINICAL Review # : low body weight mediates the relationship between HIV infection and low bone mineral density: a meta-analysis. J Clin Endocrinol Metab (2007) 1.42
The randomised controlled trial to meta-analysis ratio: original data versus systematic reviews in the medical literature. N Z Med J (2007) 1.40
Use of automated home blood pressure monitoring in pregnancy: is it safe? Am J Obstet Gynecol (2002) 1.40
Bone metabolism during long-term treatment with imatinib. Leuk Lymphoma (2013) 1.40
Evaluation of the FRAX and Garvan fracture risk calculators in older women. J Bone Miner Res (2011) 1.39
Prolonged antiresorptive activity of zoledronate: a randomized, controlled trial. J Bone Miner Res (2010) 1.37
Enhanced osteoclastogenesis in patients with tophaceous gout: urate crystals promote osteoclast development through interactions with stromal cells. Arthritis Rheum (2008) 1.36
In vitro and in vivo effects of adiponectin on bone. Endocrinology (2009) 1.35
Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res (2011) 1.32
A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Hum Mol Genet (2002) 1.32
Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency. J Clin Endocrinol Metab (2005) 1.30
Cultural translation of interventions: diabetes care in American Samoa. Am J Public Health (2010) 1.29
Acute Coronary Syndrome patients in New Zealand receive less invasive management when admitted to hospitals without invasive facilities. N Z Med J (2004) 1.29
Modulation of osteoclastogenesis by fatty acids. Endocrinology (2008) 1.25
Fat mass is an important predictor of parathyroid hormone levels in postmenopausal women. Bone (2005) 1.25
Management of patients admitted with an Acute Coronary Syndrome in New Zealand: results of a comprehensive nationwide audit. N Z Med J (2004) 1.24
What do people with glaucoma know about their condition? A comparative cross-sectional incidence and prevalence survey. Clin Experiment Ophthalmol (2008) 1.23
Pathogenesis and management of Paget's disease of bone. Lancet (2008) 1.21
The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res (2015) 1.18
Multistage genome-wide association meta-analyses identified two new loci for bone mineral density. Hum Mol Genet (2013) 1.17
Vitamin D insufficiency and health outcomes over 5 y in older women. Am J Clin Nutr (2009) 1.17
Association between primary hyperparathyroidism and increased body weight: a meta-analysis. J Clin Endocrinol Metab (2004) 1.16
Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. J Bone Miner Res (2007) 1.16
Patients admitted with an acute coronary syndrome (ACS) in New Zealand in 2007: results of a second comprehensive nationwide audit and a comparison with the first audit from 2002. N Z Med J (2010) 1.15
Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms. J Bone Miner Res (2007) 1.15
The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women. J Clin Endocrinol Metab (2008) 1.14
Age-, gender-, and weight-related effects on levels of 25-hydroxyvitamin D are not mediated by vitamin D binding protein. Clin Endocrinol (Oxf) (2007) 1.12
Calcium supplements increase risk of myocardial infarction. J Bone Miner Res (2015) 1.11
Parallel phosphatidylinositol-3 kinase and p42/44 mitogen-activated protein kinase signaling pathways subserve the mitogenic and antiapoptotic actions of insulin-like growth factor I in osteoblastic cells. Endocrinology (2003) 1.10
Strontium and cardiovascular events. Ann Rheum Dis (2013) 1.09
Population-specific influence of SLC2A9 genotype on the acute hyperuricaemic response to a fructose load. Ann Rheum Dis (2013) 1.08